ArticleAnnals of internal medicine2012
Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series.
Article in Annals of internal medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 53 citations in OpenAlex.
- Targeting the Gut Microbiota with Herbal Compounds from Traditional Chinese Medicine: A Mechanistic Synthesis of a Novel Therapeutic Approach for Ulcerative Colitis.Journal of inflammation research · 2026Review
- Review
- Botanical Medicines Cryptolepis sanguinolenta, Artemisia annua, Scutellaria baicalensis, Polygonum cuspidatum, and Alchornea cordifolia Demonstrate Inhibitory Activity Against Babesia duncani.Frontiers in cellular and infection microbiology · 2021Article
- Evaluation of Natural and Botanical Medicines for Activity Against Growing and Non-growing Forms ofFrontiers in medicine · 2020Article
- Targeting Metalloenzymes for Therapeutic Intervention.Chemical reviews · 2019Review
- Heavy Consumption of Alcohol is Not Associated With Worse Outcomes in Patients With Idiosyncratic Drug-induced Liver Injury Compared to Non-Drinkers.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2018Article
- Flavocoxid exerts a potent antiviral effect against hepatitis B virus.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Article
- Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians.The American journal of gastroenterology · 2017Article
- Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis.Nature reviews. Rheumatology · 2016Review
- Medical Plant Extracts for Treating Knee Osteoarthritis: a Snapshot of Recent Clinical Trials and Their Biological Background.Current rheumatology reports · 2015Review
- Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system.Gastroenterology · 2015Article
- Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.Gastroenterology · 2015Observational
- Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance.PloS one · 2013Article
- Herbal medicine for rheumatic diseases: promises kept?Current rheumatology reports · 2012Review
Corrections and comments
- SummaryForPatientsIn
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundFlavocoxid is a prescription medical food that is used to treat osteoarthritis. It is a proprietary blend of 2 flavonoids, baicalin and catechins, which are derived from the botanicals Scutellaria baicalensis and Acacia catechu, respectively.
objectiveTo describe characteristics of patients with acute liver injury suspected of being caused by flavocoxid.
designCase series.
settingDrug-Induced Liver Injury Network Prospective Study ongoing at multiple academic medical centers since 2004. PATIENTS: Four adults with liver injury. MEASUREMENTS: Clinical characteristics, liver biochemistry values, and outcomes.
resultsAmong 877 patients enrolled in the prospective study, 4 had liver injury suspected to have been caused by flavocoxid. All were women; ages ranged from 57 to 68 years. All developed symptoms and signs of liver injury within 1 to 3 months after initiating flavocoxid. Liver injury was characterized by marked elevations in levels of alanine aminotransferase (mean peak, 1268 U/L; range, 741 to 1540 U/L), alkaline phosphatase (mean peak, 510 U/L; range, 286 to 770 U/L), and serum bilirubin (mean peak, 160.7 µmol/L [9.4 mg/dL]; range, 34.2 to 356 µmol/L [2.0 to 20.8 mg/dL]). Liver biochemistry values decreased to the normal range within 3 to 12 weeks after flavocoxid was stopped, and all patients recovered without experiencing acute liver failure or chronic liver injury. Causality was adjudicated as highly likely in 3 patients and as possible in 1 patient. LIMITATION: The frequency and mechanism of liver injury could not be assessed.
conclusionFlavocoxid can cause clinically significant liver injury, which seems to resolve within weeks after cessation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.